AEterna Zentaris Inc. (AEZS)

[Investwisely123]

Michael Ward current CEO of AEZS, prior to AEZS served as Chief Compliance & Legal Officer and Corporate Secretary to Sagent Pharmaceuticals, and handled its sale to Nichi-iko Pharmaceuticals, Ltd. for $736 Million Dollars in 2016. Michael Ward is a deal maker. He was brought into AEZS for the purpose of selling the company in my opinion. Some strong indications that AEZS will be sold in its entirety are the settlement of two lawsuits in the past month right before Macrilen approval in Europe, no mention of expanding AEZS drug pipeline to any other drugs besides Macrilen, very little news and talk about the future of AEZS, and the very strong need by Novo Nordisk for Macrilen to compliment its drugs for treating AGHD. As always, do your own due diligence.